Search Within

Carol A Aghajanian

Formats
  1. Journal Article (325)
  2. Meeting Abstract (284)
  3. Review (3)
  4. Book Section (1)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Department of Medicine (615)
  2. GDMT, Medicine (615)
  3. Gynecologic Medicine Service (615)
  4. Gynecology Disease Management Team (615)
  5. Solid Tumor Oncology Division (615)
  6. Surgery (229)

More Groups

People
  1. Nadeem Abu-Rustum (126)
  2. Paul Sabbatini (125)
  3. Alexia Iasonos (116)
  4. David Spriggs (105)
  5. Roisin O'Cearbhaill (99)
  6. Martee Hensley (94)

More People

Years
  1. 2025 (24)
  2. 2024 (38)
  3. 2023 (42)
  4. 2022 (45)
  5. 2021 (35)
  6. 2020 (61)

More Years

Publications
  1. Gynecologic Oncology (200)
  2. Journal of Clinical Oncology (150)
  3. International Journal of Gynecological Cancer (57)
  4. Clinical Cancer Research (30)
  5. Annals of Oncology (28)
  6. Cancer (15)

More Publications

Publishers
  1. Elsevier B.V. (204)
  2. American Society of Clinical Oncology (156)
  3. Lippincott Williams & Wilkins (59)
  4. American Association for Cancer Research (54)
  5. Oxford University Press (30)
  6. Elsevier Inc. (21)

More Publishers

Results (615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial
    Meeting Abstract

    Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Optimizing mainstreaming of genetic testing in parallel with ovarian and endometrial cancer tumor testing: How do we maximize our impact?
    Journal Article

    Liu, Y. L.; Sia, T. Y.; Varice, N.; Wu, M.; Byrne, M.; Khurram, A.; Kemel, Y.; Sheehan, M.; Galle, J.; Sabbatini, P.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Characterization of recurrent gene amplifications in copy numerhigh endometrial cancers
    Meeting Abstract

    Roy, A.; Dagher, C.; Abu-Rustum, N. R.; Aghajanian, C.; Mueller, J. J.; Weigelt, B.; Chui, M. H.; Boroujeni, A. M.
    Virchows Archiv (2024)

    Fulltext@MSK | Save
  • ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype
    Journal Article

    Brodeur, M. N.; Selenica, P.; Ma, W.; Moufarrij, S.; Dagher, C.; Basili, T.; Abu-Rustum, N. R.; Aghajanian, C.; Zhou, Q.; Iasonos, A.; more...
    Molecular Oncology (2024)

    Fulltext@MSK | Save
  • Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer
    Journal Article

    Rios-Doria, E.; Abu-Rustum, N. R.; Alektiar, K. M.; Makker, V.; Liu, Y. L.; Zamarin, D.; Friedman, C. F.; Aghajanian, C.; Ellenson, L. H.; Chiang, S.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
    Journal Article

    Brown, J.; Miller, A.; Holman, L. L.; Backes, F.; Nagel, C.; Bender, D.; Miller, D. S.; Powell, M. A.; Westin, S. N.; Bonebrake, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)
    Meeting Abstract

    Erickson, B. K.; Enserro, D.; Lankes, H. A.; Dockery, L. E.; Ghamande, S. A.; Oliver, M. T.; Gressel, G. M.; Castellano, T.; Ratner, E.; Deery, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Racial/ethnic distribution of participants in NRG oncology clinical trials: 2014-2023
    Meeting Abstract

    Dignam, J. J.; Romitti, P. A.; Yom, S. S.; Feng, F. Y.; Bradley, J. D.; Mehta, M. P.; Bruner, D. W.; Wenzel, J.; Mamounas, E. P.; George, T. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types
    Meeting Abstract

    Gormally, M.; Repetto, M.; Jee, J.; Chang, J. C.; Selenica, P.; Gazzo, A.; Richards, A. L.; Donoghue, M.; Aghajanian, C.; Reis-Filho, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
    Meeting Abstract

    Green, A.; Zhou, Q.; Iasonos, A.; Zammarrelli, W.; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Hom, V.; Erinjeri, J. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save